Atrx loss as a promising screening tool for the identification of diffuse midline glioma subtype, H3K27/MAPKinase co-altered
Acta Neuropathol Commun. 2024 Jun 27;12(1):105. doi: 10.1186/s40478-024-01818-8. NO ABSTRACT PMID:38926805 | DOI:10.1186/s40478-024-01818-8